白皮书
赞助商的风险开发和运行自己的DCT技术
2022年6月22日
通过提交此表格,您同意我们的使用条款and隐私政策。您提供的信息可能会收集并自动存储在我们的数据库中,可用于向您发送有关IQVIA和我们的服务的其他信息。此类信息也可以转移到其他国家 /地区的IQVIA公司。版权所有©2018-2022 IQVIA Holdings Inc.及其分支机构。版权所有。

It is almost cliché now to mention that the COVID-19 pandemic was the proving ground for Decentralized Clinical Trials (DCTs) – the perfect catalyst to accelerate their development and adoption. With site and participant experience backing the benefit of DCTs, there is an understandable push by sponsors to scale remote research among their portfolio of clinical trials. To keep up, many sponsors are considering building their own, purchasing, or licensing DCT technology.

Related solutions